CytelRAND™
Modern Centralized Clinical Study Randomization

Traditional Approach Shortcomings

Reliable patient randomization is crucial to executing any clinical study. Yet, more and more sponsors are reconsidering their traditional approaches, especially reliance on in-house randomizing software that‘s adequate for one trial, but must be extensively modified - or even rewritten for each successive trial.

Cytel’s centralized randomization software solutions are applicable to most trial designs, and for drug therapies, biologics and medical device studies across all therapeutic areas.

Why CytelRAND™?

Developed collaboratively for use originally at Wyeth and Merck Research Labs, CytelRAND™ solutions are now available to all sponsor organizations.

The service provides a single patient randomization source for both early and late stage studies. CytelRAND™ users enjoy a solution that’s widely applicable and additional includes important design and assessment capabilities not found in traditional randomizing software:

• simulation tools to assess alternative randomization approaches
• operational randomization schemes for even more complicated trial designs
• a quality assurance monitor assuring that randomizing is proceeding correctly

CytelRAND™ solutions have been extensively tested for statistical validity and accuracy in operation. These validation tests are thoroughly documented and accepted by international regulators.

Contact us to discuss how CytelRAND™ can continuously assure reliable treatment randomizing and increase your own clinical efficiencies.